Travere Therapeutics (TVTX) Tops Q3 EPS by 333c

Travere Therapeutics (NASDAQ: TVTX) reported Q3 EPS of $2.27, $3.33 better than the analyst estimate of ($1.06). Revenue for the quarter came in at $37.09 million versus the consensus estimate of $57.78 million.

For earnings history and earnings-related data on Travere Therapeutics (TVTX) click here.

You May Also Be Interested In

• Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
• Morgan Stanley Resumes American Eagle Outfitters (AEO) at Equalweight
• Morgan Stanley Resumes Kohl's (KSS) at Underweight